|
Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease Clinical research trials and Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease. Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease clinical trial. Human subjects frequently get the finest healthcare available for their Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease  Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease
Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease
For Condition: Anemia, Sickle Cell,Blood Disease
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To continue to follow the newborn cohort and the over-35 years of age cohort from the Cooperative Study of Sickle Cell Disease (CSSCD), a study of the natural history of sickle cell disease.
Details: BACKGROUND: The Cooperative Study of Sickle Cell Disease was initiated in 1977 to determine the natural history of sickle cell disease from birth to death in order to identify those factors contributing to the morbidity and mortality of the disease. Patients in the study had been followed previously in CSSCD. Follow-up of the newborn cohort provided data demonstrating that life-threatening septicemia can occur as early as four months of age, and that the incidence of septicemia in children with sickle cell disease is higher than previously reported. Serial measurements of pocked or vesiculated red blood cells determined the onset of splenic dysfunction. The loss of splenic function has been characterized by genotype and the observed patterns of loss of splenic function were different developmentally depending on the sickle hemoglobinopathy syndrome. Growth retardation, which becomes obvious around seven years of age, has no relationship to reported family income. Prophylactic oral penicillin can decrease morbidity and mortality associate with pneumococcal septicemia. The newborn infant cohort was unique in determining issues related to the natural history of the disease because the information was prospective and has been captured in the database. The complex database permitted an opportunity to determine outcomes, risk factors, and the application of the severity index to determine the spectrum of severity. Follow-up of the over-35 cohort is important because it was not so long ago that it was estimated that 50 percent of patients with sickle cell anemia in the United States died before their twentieth birthday. However, data accumulated over the past eight years by the CSSCD demonstrates that this is incorrect. Survival beyond the age of forty suggests that surviving patients are somehow different from other patients with a high mortality in the earlier years. Therefore, they constitute a cohort of special interest, and the reasons for prolonged survival in this disease remain to be well documented prospectively. Technology is now available to identify genetic differences which may influence survival. Based on the findings of the earlier CSSCD, the Blood Diseases and Resources Advisory Committee Red Cell Working Group recommended this initiative which was approved by the May 1987 National Heart, Lung, and Blood Advisory Council. The Request for Proposals was released in February 1988 and awards made in October 1988. DESIGN NARRATIVE: Follow-up of the newborn cohort continued in order to better understand the severity, onset of early organ damage, and risk factors. Patients were given an entry evaluation consisting of interim history, complete physical examination, complete blood count, urinalysis, blood drawn for haplotype determination and for the serum bank, magnetic resonance imaging of the brain, pulmonary function tests with arterial blood gas, and psychomotor tests. Patients had interim assessments at six months and annual assessments as well as an exit assessment in the fourth or fifth years. The exit assessment was the same as the entry assessment. Follow-up of the over-35 cohort continued in order to better understand factors that contribute to longevity. Entry evaluation consisted of interim history, complete physical examination, complete blood count, urinalysis, blood drawn for haplotype determination and for the serum bank, cardiac MUGA, and renal and pulmonary function tests. Follow-up was yearly with an exit evaluation in the fourth or fifth years.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Male
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: 3001;
Study Start Date: October 1988
Record last reviewed: May 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005300
Other Blood Disease Studies:
1. Prevention of Cerebral Infarction in Sickle Cell Anemia - Comprehensive Sickle Cell Center
2. Vietnam Era Twin (VET) Registry
3. Anemia and Surgery: Indications For Transfusion
4. Hepatitis C in Clinically Discordant Hemophilic Siblings
5. Epidemiology and Immunology of Hemophilia A Inhibitors
Related Studies:
Other Blood Disease Clinical Trials
Other Clinical Trials
Other Clinical Trials
Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease
|
|
|
|
|
|
|
|
